4.4 Article

Radiotherapy as a Treatment Option for Local Disease Control in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type

期刊

DERMATOLOGY
卷 238, 期 5, 页码 967-976

出版社

KARGER
DOI: 10.1159/000522053

关键词

Radiotherapy; Chemotherapy; B-cell lymphoma; Primary cutaneous diffuse large B-cell lymphoma; leg type

资金

  1. Jubilaumsstiftung von SwissLife [1406/M, 1412/M]
  2. Promedica Stiftung [KFS-4243-08-2017]
  3. Swiss Cancer Research Foundation [PMPDP3_151326]
  4. Clinical Research Priority Program (CRPP) of the University of Zurich [PPRC-2019-20]
  5. Swiss National Science Foundation
  6. European Academy of Dermatology and Venereology

向作者/读者索取更多资源

A retrospective analysis of 20 PCDLBCL, LT patients showed that radiotherapy provided good local disease control but did not significantly improve the overall risk of disease progression. Following progression, radiotherapy could still easily be combined with systemic treatment. The strength of this analysis needs to be evaluated in a larger patient cohort.
Background: Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL, LT) is an aggressive lymphoma variant. Anthracycline-based chemotherapy with rituximab is recommended as first-line treatment. Radiotherapy (RT) has been considered as a therapeutic option for local disease control in patients with solitary or localized lesions. Methods: We report the results of a retrospective analysis of PCDLBC, LT patients treated either with RT alone or with physician's decision as first-line treatment, aiming to assess disease progression and/or first recurrence in these treatment groups. Results: We retrospectively analyzed 20 patients treated either with RT alone (n = 8) or with investigator's choice treatment (n = 12), which included chemotherapy alone or combined with local therapy (RT and wide local excision). Complete response (CR) was achieved in 8 patients from the first group and 9 patients from the second group, with 1 treatment failure. Six patients treated with RT alone progressed with a median time to progression (TTP) of 12.5 months. In the second group, 5 patients progressed with a median TTP of 5.2 months. RT showed good local disease control in both groups without any skin relapses during the follow-up period. Conclusion: RT as first-line monotherapy followed by watchful waiting did not significantly improve the overall risk of disease progression but resulted in good local disease control. After progression, RT could still easily be combined with systemic treatment. The strength of this analysis needs to be evaluated in a larger patient cohort.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据